GILD
Gilead Sciences, Inc.
GILD lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
GILD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Strong | |
| Healthy |
GILD's cash flow and balance sheet are currently healthy, and its revenue is stable, but its profitability is weak.
GILD PE Valuation
GILD has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 20x next year's earnings.
GILD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect GILD to return to profit, with revenue growing. However, they disagree widely on these estimates.
GILD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.61 | — |
| Q3 2026 | -$3.15 | -149% |
| Q2 2026 | -$2.66 | -153% |
| Q1 2026 | $7.35 | +54% |
| Q4 2025 | $6.78 | +1684% |
| Q3 2025 | $6.46 | +7078% |
| Q2 2025 | $5.03 | +513% |
| Q1 2025 | $4.76 | +1222% |
| Q4 2024 | $0.38 | -92% |
GILD has swung to a loss: it lost $3.15 per share over the past year, after a profit the year before.
GILD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.3B | +6.8% |
| Q2 2026 | $7.8B | +10% |
| Q1 2026 | $7B | +4.4% |
| Q4 2025 | $7.9B | +4.7% |
| Q3 2025 | $7.8B | +3% |
| Q2 2025 | $7.1B | +1.8% |
| Q1 2025 | $6.7B | -0.3% |
| Q4 2024 | $7.6B | +6.4% |
GILD's revenue has grown year over year for six quarters in a row: $8.3B last quarter, up 6.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 42% | -1.1 points |
| Q2 2026 | -133% | -168 points |
| Q1 2026 | 37% | +3.6 points |
| Q4 2025 | 25% | -7.4 points |
| Q3 2025 | 43% | +31 points |
| Q2 2025 | 35% | -3.1 points |
| Q1 2025 | 34% | +98 points |
| Q4 2024 | 32% | +9.7 points |
GILD's operating margin was 42% last quarter, down 1.1 points from the same quarter a year ago.
GILD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.8B | +21% |
| Q2 2026 | $3.4B | +377% |
| Q1 2026 | $2.4B | +47% |
| Q4 2025 | $3.1B | +10% |
| Q3 2025 | $4B | -5% |
| Q2 2025 | $720M | -40% |
| Q1 2025 | $1.7B | -22% |
| Q4 2024 | $2.8B | +45% |
GILD's free cash flow has been positive every quarter for seven years: $13.8B over the past year, up 50% from the year before.
GILD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +8M shares |
| 1 year | -0.2% | -3M shares |
| 3 years | -0.5% | -6M shares |
| 5 years | -0.9% | -11M shares |
| Available history | -2% | -26M shares |
GILD has 1.3B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $370M |
| Q2 2026 | $355M |
| Q1 2026 | $419M |
| Q4 2025 | $230M |
| Q3 2025 | $435M |
| Q2 2025 | $527M |
| Q1 2025 | $730M |
| Q4 2024 | $350M |
GILD spent $1.4B buying back its own shares over the past year, down 33% from the year before.
GILD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.7x | Healthy |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 2.4x | Moderate |
| Q1 2025 | 2.0x | Healthy |
| Q4 2024 | 8.2x | High |
| Q3 2024 | 10.1x | High |
| Q2 2024 | 5.0x | High |
GILD's net debt is about 1.4 years of its operating earnings (EBITDA), down from 2.0 years a year ago.
GILD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.7 | Neutral |
| Stochastic | 83.3 | Overbought |
GILD's weekly RSI is 69 (neutral) and its Stochastic is 83 (overbought).
GILD PE vs Healthcare Sector
| Metric | GILD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GILD has no meaningful PE right now: it lost money over the past year.
GILD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $158.1 | 6.3% above |
| 20 week MA | $146.4 | 15% above |
| 50 week MA | $138.9 | 21% above |
| 100 week MA | $124.2 | 35% above |
| 200 week MA | $101.1 | 66% above |
GILD is in an uptrend: it's above all five of its weekly moving averages, and 66% above its 200-week average.
GILD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.0 | $57.1 | -13% |
| 2021 | $57.1 | $72.5 | +27% |
| 2022 | $72.5 | $84.8 | +17% |
| 2023 | $84.8 | $81.0 | -4.4% |
| 2024 | $81.0 | $94.1 | +16% |
| 2025 | $94.1 | $124.7 | +33% |
| 2026 YTD | $124.7 | $168.0 | +35% |
GILD has finished higher in four of the last six years. It's up 35% so far in 2026.